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Optimal SBP targets in routine clinical care
Lisanne A. Gitselsa, Elena Kulinskayaa, Ilyas Bakbergenulya, and Nicholas Steelb
Objective: Compare outcomes of intensive treatment of SBP
to less than 120mmHg versus standard treatment to less
than 140mmHg in the US clinical Systolic Blood Pressure
Intervention Trial (SPRINT) with similar hypertensive patients
managed in routine primary care in the United Kingdom.
Methods: Hypertensive patients aged 50–90 without
diabetes or chronic kidney disease (CKD) were selected in
SPRINT and The Health Improvement Network (THIN)
database. Patients were enrolled in 2010–2013 and
followed-up to 2015 (SPRINT N¼4112; THIN N¼8631).
Cox’s proportional hazards regressions were fitted to
estimate the hazard of all-cause mortality or CKD (main
adverse effect) associated with intensive treatment,
adjusted for sex, age, ethnicity, smoking, blood pressure,
cardiovascular disease, aspirin, statin, number of
antihypertensive drugs at baseline, change in number of
antihypertensive drugs at trial entry, and clinical site.
Results: Almost half of the patients had intensive
treatment (43–45%). In SPRINT, intensive treatment was
associated with a decreased hazard of mortality of 0.63
(0.43–0.92), while in THIN with an increased hazard of
1.66 (1.28–2.15). In THIN, this effect was time-dependent.
Intensive treatment was associated with an increased
hazard of CKD of 2.67 (1.74–4.11) in SPRINT and 1.35
(1.08–1.70) in THIN. In THIN, this effect differed by the
number of antihypertensive drugs prescribed at baseline.
Conclusion: It appears that intensive treatment of SBP
may be harmful in the general population where all have
access to routine healthcare as with the UK National
Health Services, but could be beneficial in high-risk
patients who are closely monitored.
Keywords: antihypertensive treatment, chronic kidney
disease, clinical guidelines, hypertension, survival prospects
Abbreviations: AUC, area under the curve; CKD, chronic
kidney disease; CVD, cardiovascular disease; NICE, National
Institute of Health and Care Excellence; RCT, randomized
clinical trial; ROC, receiver operating characteristic; SIGN,
Scottish Intercollegiate Guidelines Network; SPRINT,
Systolic Blood Pressure Intervention Trial; THIN, The Health
Improvement Network primary care database
INTRODUCTION
H
igh SBP (140mmHg) is one of the leading risk
factors of the global burden of disease, attributing
to an estimated 122.2 million disease-adjusted
life-years in men and 89.9 million in women in 2016 [1].
High SBP has consistently been associated with increased
risks of cardiovascular disease (CVD) and related comor-
bidities such as chronic kidney disease (CKD) [1–3].
The results of the Systolic Blood Pressure Intervention
Trial (SPRINT) in the United States showed considerable
survival benefits of treatment of SBP to a target of less than
120mmHg compared with a target of less than 140mmHg
[4]. Following this, the American Heart Association changed
its guideline on hypertension in 2017 [3]. In its previous
version of 2003, hypertension was defined as having a SBP
of at least 140mmHg, whereas now hypertension is defined
as having a SBP of at least 130mmHg. With the change in
hypertension definition, its prevalence in the United States
increased from 32 to 46% [5].
The UK National Institute of Health and Care Excellence
(NICE) is currently reviewing its hypertension guideline [2].
Hypertension is defined as having a SBP of at least
140mmHg, which is prevalent in nearly 30% in the United
Kingdom [6]. The Scottish Intercollegiate Guidelines Net-
work (SIGN) is accredited byNICE to develop clinical guide-
lines [7]. The SPRINT results were not taken up in its latest
guideline on the prevention of CVD published in 2017, as
SIGN found that several aspects of SPRINT made the results
difficult to interpretwith respect to routine clinical practice in
Scotland [7]. Thesewere among others the short follow-upof
3.3 years compared with treatment regimes in routine prac-
tice and thewaybloodpressure (BP)wasmeasured resulting
in lower readings than if they were measured in routine
practice. SIGN, however, did acknowledge that tighter BP
targets should be considered in high-risk patients.
NICE identified several gaps in the research evidence
around the management of hypertension when the guid-
ance was updated in 2016 [2]. It recommended further
research into the optimal SBP in people with treated hyper-
tension by means of a large randomized clinical trial (RCT)
that has sufficient power to assess clinical outcomes in
people with different SBP targets [2]. An RCT, however,
is expensive and due to its strict targets that are tightly
controlled, its results can be difficult to translate to routine
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practice [7]. A large observation study could complement
RCTs by testing the effect of treatments associated with
clinical outcomes in the general population [8]. This led to
the research question: what are the survival and CKD
prospects of intensive treatment of SBP to less than
120mmHg versus standard treatment to less than
140mmHg in the US clinical trial SPRINT in comparison
with similar hypertensive patients managed in routine
primary care in the United Kingdom?
METHODS
Study design
SPRINT is an RCT which included people aged 50–90 years
with a SBP of 130–180mmHg and an increased risk of CVD
(Framingham risk score 15%) [4]. The study population
excluded people with a history of cancer, dementia, diabe-
tes, heart failure, or stroke. Patients were enrolled in
November 2010–March 2013 and followed-up to August
2015. Patients were either assigned the standard treatment
regime of lowering SBP to less than 140mmHg or the
intensive to less than 120mmHg. For more information
on SPRINT, refer to [4]. For our study, SPRINT patients
were excluded if they had a history of CKD at baseline,
were not prescribed antihypertensive drugs at trial entry, or
did not reach the target SBP in 6 months, refer to Supple-
mentary File Table S1, http://links.lww.com/HJH/B19.
Two retrospective cohorts were studied using health
records of The Health Improvement Network (THIN) pri-
mary care database. THIN records are representative of the
UK population when adjusted for sex, age, and deprivation
[9,10]. The first cohort had the same study period as SPRINT.
The second cohort had an extended study period to
increase the power of the study and to estimate the long-
term effects of SBP targets; enrolment in January 2005–
December 2013 and follow-up to January 2017. The first
cohort was a subset of the second cohort, with a maximum
follow-up of almost 5 and 12 years, respectively. The
cohorts had the same inclusion and exclusion criteria as
SPRINTwith the exception of no criterion on cardiac risk. In
addition, the selected patients had to have their SBP
reduced from 141 to 180mmHg (baseline, first measure-
ment) to either 121–140mmHg (standard treatment) or 70–
120mmHg (intensive treatment) within 6 months (second
measurement). The cut-off values of BP categories in THIN
were 1mmHg higher than in SPRINT because there was a
terminal digit bias towards zero in BP recording in primary
care [11]. The selection criteria also specified that the patient
had to have a diagnosis of hypertension at baseline or at
least one ongoing antihypertensive drug prescription in the
month prior to the baseline, and a change in antihyperten-
sive treatment in the month prior to the second measure-
ment. A change in treatment was defined as a change in
dose, drug, or number of drugs.
SPRINT data were made available by the National Heart,
Lung, and Blood Institute for the SPRINT Data Analysis
Challenge hosted by the New England Journal of Medicine
[12]. By qualifying for the challenge, we were permitted to
publish our analyses of SPRINT data. This study was
approved by THIN Scientific Review Committee and the
University of East Anglia Computing Sciences Research
Ethics Committee. Informed consent was not required for
research based on routine data.
Medical history
The outcomes were time to all-cause mortality and time to
CKD [estimated glomerular filtration rate (eGFR) to <60ml/
min per 1.73m2], measured in days. The primary exposure
was treatment of SBP. In SPRINT, BP was measured by an
automated device while unattended by a healthcare profes-
sional after the patient rested for 5min alone in a room [4]. In
contrast, in UK routine clinical practice, BP is measured by a
sphygmomanometer used by a healthcare professional with
no rest period for the patient (i.e., office BP) [2]. The second-
ary exposures were the number of antihypertensive drugs
prescribed at baseline and change in the number of antihy-
pertensive drugs prescribed at trial entry (SPRINT) or prior to
the second BP measurement (THIN). Potential confounders
were selected based on SPRINT’s baseline measures: SBP,
CVD, aspirin, statin, smoking status, and BMI. The demo-
graphicmeasures included sex, age, ethnicity (SPRINTonly),
and deprivation (THIN only). To have a meaningful refer-
ence group, baseline SBP was centred at 140mmHg and age
at 65 years. In THIN, ethnicity is not consistently recorded
with 65% being unknown [13], therefore it was not included.
In SPRINT, deprivation was not recorded [4]. For more
information on the selected medical history, refer to Table
S2, http://links.lww.com/HJH/B19.
In SPRINT, there were less than 1% missing values in
aspirin, statin, smoking status, and BMI. In THIN, there
were missing values in smoking status (23%) and BMI
(45%). Due to the high prevalence of missing values in
BMI in THIN and the insignificant association of BMI with
the outcomes time to death or CKD in SPRINT, BMI was
excluded from the analyses. Patients with missing values in
aspirin, statin, or smoking status were excluded from the
study (SPRINT< 1%; THIN¼ 23%).
Statistical analyses
Cox’s regression models were fitted to estimate the effect of
intensive treatment associated with the hazard of all-cause
mortality and the hazard of CKD. The competing risk adap-
tation of a Cox’smodelwas examined, but disregarded as the
adapted models provided similar results with the same
conclusions as the simple Cox’s models. The final models
included the covariates and interactions with treatment arm
that were significant (P< 0.05) or of substantial effect size
(jbj> 0.20) in either SPRINT or THIN using backward elimi-
nation. The main exposures and demographic covariates
were included regardless of their significance level or effect
size. The linearity of the effect of the continuous covariates
SBP and age were tested by including their quadratic form.
The proportional hazards assumption was checked by
Grambsch and Therneau’s test [14]; the effect of a violating
covariate wasmade time-dependent. Themodels included a
frailty term on clinical site to take into account the interde-
pendence of patients from the same site. The models were
assessed on overall performance, discrimination, and exter-
nal validation,usingRoyston’sR2,Harrell’s concordance, and
10-fold cross-validation, respectively [15].
A sensitivity analysis was performed based on the pro-
pensity score of receiving intensive treatment in routine
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clinical practice as observed in THIN. This score was
predicted by a logistic regression that included all baseline
information described above and a frailty term on clinical
site. The accuracy of the prediction was quantified by the
area under the curve (AUC) of the receiver operating
characteristic (ROC) [15]. By means of nearest neighbour
matching [16], patients on intensive treatment were
matched one on one to patients on standard treatment.
The final survival models were refitted on the matched
propensity score datasets of THIN.
RESULTS
Cohorts’ characteristics
With our additional selection criteria, SPRINT’s sample size
was reduced to 4165 patients, where 45% was assigned the
intensive treatment of lowering SBP to less than 120mmHg,
refer to Table 1. At each stage of the selection process, the
unadjusted hazard of mortality or CKD associated with
intensive treatment was estimated, refer to Table S1,
http://links.lww.com/HJH/B19. Comparing the results in
the original sample with our final sample, the hazards were
not significantly different.
The THIN cohort with the same SPRINT dates included
8361 patients, where 43% had their SBP reduced to
120mmHg or less, refer to Table 1. The THIN cohort with
the extended dates included 54 683 patients, where 36%
had their SBP reduced to less than 120mmHg, refer to
Table S3, http://links.lww.com/HJH/B19.
The baseline SBP was on average 11mmHg lower in
SPRINT than in THIN. This could be explained by the
different selection criteria, where in SPRINT the baseline
SBP had to be between 130 and 180mmHg whereas in
THIN this had to be between 141 and 180mmHg. In
SPRINT, the average SBP during follow-up stayed stable
after reaching the treatment target within 6 months; 135–
137mmHg in the standard and 116–120mmHg in the
intensive treatment arm, refer to Fig. 1. In THIN, however,
the average SBP increased after the treatment target was
reached within 6 months and remained levelled thereafter;
142–143mmHg in the standard and 137–138mmHg in the
intensive treatment arm, refer to Fig. 1.
Comparing the characteristics of the SPRINT cohort and
the THIN cohort with the same SPRINT dates, the average
follow-up was 3.3 and 3.4 years, respectively. The incidence
of death during follow-up was similar in both standard
treatment arms (2–3%), but was higher in the intensive
treatment arm of THIN (5%). The incidence of CKD during
follow-up was higher in the intensive treatment arms and in
THIN (1–6%). The prevalences of CVDandprescribed drugs
TABLE 1. Characteristics of Systolic Blood Pressure Intervention Trial and The Health Improvement Network cohorts with the same study
period
SPRINT THIN
Standard treatmenta Intensive treatmentb Standard treatmenta Intensive treatmentb
Number of participants 2285 1880 4743 3618
Total person-years follow-up (mean) 7439 (3.3) 6173 (3.3) 16 475 (3.5) 12 417 (3.4)
Death during follow-up 76 (3%) 45 (2%) 104 (2%) 171 (5%)
Chronic kidney disease during follow-up 32 (1%) 73 (4%) 162 (3%) 206 (6%)
SBP at baseline
Mean (SD) 145.0 (11.2) 144.3 (10.9) 159.4 (10.1) 155.9 (9.8)
Number of antihypertensive drugs at baseline
1 756 (33%) 602 (32%) 750 (16%) 915 (25%)
2 791 (35%) 626 (33%) 374 (8%) 637 (18%)
3þ 519 (23%) 418 (22%) 177 (4%) 457 (13%)
Change in number of antihypertensive drugs at entry
More 577 (25%) 908 (48%) 4010 (85%) 2422 (67%)
Less 156 (7%) 59 (3%) 228 (5%) 494 (14%)
Aspirin
Yes 1097 (48%) 929 (49%) 267 (6%) 555 (15%)
Statin
Yes 905 (40%) 759 (40%) 621 (13%) 1021 (28%)
Cardiovascular disease
Yes 324 (14%) 292 (16%) 277 (6%) 407 (11%)
Sex
Male 1501 (66%) 1212 (64%) 2730 (58%) 1760 (49%)
Age
Mean (SD) 66.5 (9.0) 66.5 (9.1) 63.5 (8.5) 65.3 (9.7)
Ethnicity
Black 806 (35%) 610 (32%) NA NA
Deprivation quintile
2 NA NA 1131 (24%) 815 (23%)
3 NA NA 1106 (23%) 808 (22%)
4 NA NA 865 (18%) 689 (19%)
5 Least NA NA 626 (13%) 484 (13%)
Smoking status
Ex 928 (41%) 762 (41%) 1558 (33%) 1320 (36%)
Yes 326 (14%) 286 (15%) 940 (20%) 644 (18%)
SPRINT, Systolic Blood Pressure Intervention Trial; THIN, The Health Improvement Network.
aStandard treatment of SBP less than 140mmHg.
bIntensive treatment of SBP less than 120mmHg.
Optimal SBP targets
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werehigher in SPRINT than inTHIN.This couldbeexplained
by the different selection criteria, where SPRINT patients had
to be at an increased risk of CVD and were therefore more
likely to be prescribed-related drugs. Furthermore, in
SPRINT these prevalences were balanced across treatment
arms, but in THIN the prevalences in the intensive treatment
arm were twice of those in the standard treatment arm. In
SPRINT, there was a similar percentage of men in each
treatment arm (64–66%), however in THIN, thereweremore
men in the standard (58%) than in the intensive treatment arm
(49%). The average agewas 66.5 in SPRINTand64.5 in THIN.
In SPRINT, the treatment arms consisted of 32–35% black
minority. Given that THIN is representative of the UK popu-
lation, 93% of the cohort is expected to be white [17], and it
was assumed this was balanced across treatment arms. In
THIN, the treatment arms had similar distribution of depri-
vation (<2% difference per quintile). SPRINT and THIN had
similar prevalence of nonsmokers, however, SPRINT had
more ex-smokers while THIN had more current-smokers.
The THIN cohort with extended dates had a longer study
period with an average follow-up of 7.8 and 7.2 years in the
standard and intensive treatment arm, respectively. This
resulted in a higher percentage deaths and CKD observed;
the standard treatment arm had 11% deaths and 14% CKD,
while the intensive treatment arm had 13% deaths and 16%
CKD. The baseline characteristics of the extended THIN
cohort were similar to those of the THIN cohort with the
same SPRINT dates, with the exception that sex was bal-
anced across treatment arms and the prevalences of CVD
and prescribed drugs were higher in the extended cohort.
This is in accordance with the literature, which showed that
the incidence of CVD has fallen in the past decades [18,19]
and therefore related drugs has fallen as well.
All-cause mortality
The leanest survival model of all-cause mortality included
treatment arm, number of antihypertensive drugs at base-
line, change in the number of antihypertensive drugs at
trial entry, aspirin, statin, CVD, sex, age, ethnicity (only
SPRINT), deprivation (only THIN), smoking status, and
clinic, refer to Fig. 2 and Table S4, http://links.lww.com/
HJH/B19. In SPRINT, compared with the standard treat-
ment, the intensive treatment was associated with a
decreased hazard of mortality of 0.63 (0.43–0.92). In THIN,
the intensive treatment had a time-dependent effect, where
it was associated with higher increased hazard in the first
100
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FIGURE 1 SBP during follow-up by treatment arm and cohort. Standard treatment of SBP less than 140mmHg. yIntensive treatment of SBP less than 120mmHg.
Factor
Antihypertensive 
   treatment
Number of antihyp.
   drugs at baseline
Change in number of 
   antihyp. drugs at entry
Category
Standard
Intensive <1 yr
Intensive >=1 yr
0/1 drug
2+ drugs
Same/less
More
SPRINT
HR (95%CI)
0.63 (0.43−0.92)
1.35 (0.88−2.05)
1.54 (1.01−2.34)
THIN_spr
HR (95%CI)
2.40 (1.35−4.24)
1.51 (1.14−2.02)
1.33 (0.96−1.84)
1.01 (0.74−1.38)
THIN_ext
HR (95%CI)
1.35 (1.11−1.65)
1.20 (1.14−1.27)
1.19 (1.11−1.26)
0.93 (0.88−0.99)
0.5 1 1.5 2 2.5 3 3.5
Adjusted Hazard Ratio
SPRINT 2010−15
THIN_spr 2010−15
THIN_ext 2005−17
FIGURE 2 Adjusted effects of antihypertensive treatment associated with the hazard of all-cause mortality. The Health Improvement Network_spr is the Health Improve-
ment Network cohort with the same study period as Systolic Blood Pressure Intervention Trial of 2010–15. The Health Improvement Network_ext is the Health Improve-
ment Network cohort with extended study period of 2005–2017. Standard treatment of lowering SBP to less than 140mmHg. Intensive treatment of lowering SBP to less
than 120mmHg. In Systolic Blood Pressure Intervention Trial, there was no time-dependent effect of antihypertensive treatment. Hazards ratios adjusted for listed factors,
cardiovascular disease, aspirin, statin, sex, age, ethnicity (only Systolic Blood Pressure Intervention Trial), deprivation (only The Health Improvement Network), smoking
status, and clinic.
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year [SPRINT dates: 2.40 (1.35–4.24), extended dates: 1.35
(1.11–1.65)] than in subsequent years [SPRINT dates: 1.51
(1.14–2.02), extended dates: 1.20 (1.14–1.27)]. Compared
with no or one antihypertensive drug prescription at base-
line, two or more prescriptions was associated with an
increased hazard of mortality of 1.35 (0.88–2.05) in the
SPRINT cohort, 1.33 (0.96–1.84) in the THIN cohort with
SPRINT dates, and 1.19 (1.11–1.26) in the THIN cohort with
extended dates. Compared with the same number or fewer
antihypertensive drug prescriptions at trial entry, additional
prescriptions was associated with an increased hazard of
mortality of 1.54 (1.01–2.34) in the SPRINT cohort. How-
ever, in the THIN cohort with SPRINT dates it was not
associated with the hazard of mortality [1.01 (0.74–1.38)]
and in the THIN cohort with extended dates it was associ-
ated with a decreased hazard of mortality of 0.93 (0.88–
0.99). Finally, in both SPRINT and THIN, there were no
interaction effects between treatment arm and the other
covariates, indicating that the effect of intensive treatment
associated with the hazard of mortality was the same for
different groups of patients, such as for men and women.
For model performance statistics, refer to Table S4, http://
links.lww.com/HJH/B19.
Chronic kidney disease
The leanest survival model of CKD included treatment arm,
number of antihypertensive drugs at baseline, change in the
number of antihypertensive drugs at trial entry, SBP, aspirin,
CVD, sex, age, ethnicity (only SPRINT), deprivation (only
THIN), smoking status, and clinic, refer to Fig. 3 andTable S5,
http://links.lww.com/HJH/B19. In the THIN cohort with
extended dates, the hazard of CKD associated with intensive
treatment depended on the number of antihypertensive
drugs prescribed at baseline. The hazard of CKD increased
with the number of drugs prescribed at baseline and was
higher with the intensive treatment if less than two drugs
were prescribed at baseline. Compared with the standard
treatment and no antihypertensive drug prescription at base-
line, the standard treatmentwith 1, 2, or 3þprescriptionswas
associated with an increased hazard of CKD of 1.37 (1.27–
1.49), 1.86 (1.71–2.02), or 2.51 (2.28–2.75), respectively.
Comparedwith the standard treatment and no antihyperten-
sive drug prescription at baseline, the intensive treatment
with 0, 1, 2, or 3þ prescriptions was associated with an
increased hazard of CKD of 1.15 (1.05–1.25), 1.44 (1.32–
1.58), 1.77 (1.61–1.95), or 2.26 (2.04–2.50), respectively. In
the THIN cohort with SPRINT dates, compared with the
standard treatment with 0/1 antihypertensive drug prescrip-
tion at baseline, the standard treatment with 2þ prescrip-
tions, the intensive treatment with 0/1 prescription, or the
intensive treatmentwith 2þprescriptionwas associatedwith
an increased hazard of CKD of 1.09 (0.67–1.75), 1.35 (1.05–
1.73), or 1.80 (1.28–2.53), respectively. These hazards were
higher in the SPRINT cohort; with an increased hazard of
CKD of 1.19 (0.57–2.46), 2.57 (1.35–4.90), or 3.38 (1.81–
6.32), respectively. Additional antihypertensive drug pre-
scription at trial entry was associated with an increased
hazard of CKD, ranging from 1.13 (0.85–1.50) in the THIN
cohort with SPRINT dates to 1.23 (1.16–1.30) in the THIN
cohortwith extendeddates to 1.49 (0.94–2.34) in the SPRINT
cohort. For model performance statistics, refer to Table S5,
http://links.lww.com/HJH/B19.
Sensitivity analysis
The ROC curve of the predicted propensity score of receiv-
ing intensive treatment in the THIN cohorts had an AUC of
63–70%, meaning that the prediction of intensive treatment
was of low accuracy. The propensity score matching
reduced the THIN cohort with SPRINT dates by 14% to
7236 patients and the THIN cohort with extended dates by
28% to 39 512 patients. The final survival models of all-
cause mortality and CKD fitted on the matched propensity
score datasets produced very similar hazard ratios as the
ones presented above and had slightly wider confidence
intervals due to the reduced sample sizes, refer to Tables S4
and S5, http://links.lww.com/HJH/B19.
DISCUSSION
The current study estimated the survival and CKD prospects
of intensive treatment of SBP to less than 120mmHg versus
Factor
Antihypertensive treatment 
   & number of antihyp.
   drugs at baseline
Change in number of
   antihyp. drugs at entry
Category
Standard 0 drug
Standard 1 drug
Standard 2 drugs
Standard 3+ drugs
Intensive 0 drug
Intensive 1 drug
Intensive 2 drugs
Intensive 3+ drugs
Same/less
More
SPRINT
HR (95%CI)
1.19 (0.57−2.46)
2.57 (1.35−4.90)
3.38 (1.81−6.32)
1.49 (0.94−2.34)
THIN_spr
HR (95%CI)
1.09 (0.67−1.75)
1.35 (1.05−1.73)
1.80 (1.28−2.53)
1.13 (0.85−1.50)
THIN_ext
HR (95%CI)
1.37 (1.27−1.49)
1.86 (1.71−2.02)
2.51 (2.28−2.75)
1.15 (1.05−1.25)
1.44 (1.32−1.58)
1.77 (1.61−1.95)
2.26 (2.04−2.50)
1.23 (1.16−1.30)
0.3 0.8 1.3 1.8 2.3 2.8 3.3 3.8 4.3
Adjusted Hazard Ratio
SPRINT 2010−15
THIN_spr 2010−15
THIN_ext 2005−17
FIGURE 3 Adjusted effects of antihypertensive treatment associated with the hazard of chronic kidney disease. The Health Improvement Network_spr is the Health
Improvement Network cohort with the same study period as Systolic Blood Pressure Intervention Trial of 2010–2015. The Health Improvement Network_ext is the Health
Improvement Network cohort with extended study period of 2005–2017. Standard treatment of lowering SBP to less than 140mmHg. Intensive treatment of lowering SBP
to less than 120mmHg. In Systolic Blood Pressure Intervention Trial and The Health Improvement Network_spr, the interaction of antihypertensive treatment with number
of antihypertensive drugs at baseline had the levels: standard treatment with 0/1 drug (reference category), standard treatment with 2þ drugs, intensive treatment with 0/
1 drug, and intensive treatment with 2þ drugs. Hazards ratios adjusted for listed factors, cardiovascular disease, aspirin, SBP, sex, age, ethnicity (only Systolic Blood
Pressure Intervention Trial), deprivation (only The Health Improvement Network), smoking status, and clinic.
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standard treatment to less than 140mmHg in hypertensive
patients aged 50–90 without cancer, CKD, dementia, dia-
betes, heart failure, or stroke using RCT data and electronic
health records.
The current study found that intensive treatment was
associated with survival benefits in SPRINT, but survival
harms in THIN. Furthermore, there was a time-dependent
effect of intensive treatment in THIN, with higher hazards in
the first year than in subsequent years. This findingmight be
explained by the fact that after the SBP reached the target
level, it levelled off to an average of 142 and 137mmHg in
the standard and intensive treatment groups, respectively.
The UK clinical guideline recommends a SBP target of
140mmHg in hypertensive patients [2], therefore there is
no apparent reason to keep SBP below 120mmHg. This
study also found that intensive treatment was associated
with an increased hazard of CKD. The reason for higher
estimated hazards in SPRINT might be explained by the fact
that in SPRINT the average SBP of the treatment groups
remained at the target levels during follow-up whereas in
THIN they converged after the target levels were reached.
Furthermore, this study found that patients with polyphar-
macy tended to have worse survival and CKD prospects. In
both SPRINT and THIN, treatment effects did not differ by
sex or age. Finally, the models fitted on the THIN cohort
with an average follow-up of 7.8 years estimated smaller
hazards and performed better than the models fitted on the
other cohorts with an average follow-up of 3.3 years.
SPRINT BP readings are not directly comparable with BP
readings obtained in other trials and routine clinical prac-
tice, due to its unusual way of measuring BP by an auto-
mated device unattended by a healthcare professional [4].
The benefit of an unobserved automated BP measurement
is that it removes the ‘white-coat’ effect where BP spikes in a
clinical setting [20]. Removing this effect meant that BP
measurements were standardized across the sites of the
SPRINT study [20]. Health professionals expect that the BP
readings of SPRINT are between 5 and 20mmHg lower than
the usual office BP readings [21]. In the extreme case of
20mmHg difference, SPRINT’s standard treatment target is
of reducing SBP to less than 160mmHg and its intensive
treatment target to less than 140mmHg. In this extreme
case, we would expect that the intensive treatment would
improve clinical outcomes. SPRINT reported that intensive
treatment improved the risk of heart failure and mortality,
but did not improve the risk of stroke [4], which is a peculiar
finding as the risk of stroke is more responsive to BP [21]. A
meta-analysis of 32 clinical trials including approximately
105 000 patients, studied the effect of reducing SBP to less
than 150, 140, or 130mmHg on the risk of stroke, coronary
events, and death [22]. This meta-analysis reported
improved outcomes associated with SBP reduced to less
than 150 or 140mmHg, but only improved stroke outcomes
with SBP reduced to less than 130mmHg. Another meta-
analysis of 19 clinical trials including approximately 45 000
patients with a mean follow-up of 3.8 years, studied the
effect of intensive lowering of SBP on the risk of cardio-
vascular events, renal events, and death [23]. Here, the
intensive and standard treatment group had a mean SBP
of 133 and 140mmHg, respectively. This meta-analysis
reported no significant difference between treatment
groups with respect to the risk of heart failure, cardiovas-
cular death, all-cause mortality, and CKD. An observational
study based on US electronic health records including
approximately 400 000 patients with a mean follow-up of
4.0 years, found that the hazards of mortality and chronic
kidney disease associated with SBP is a U-shaped function
with the lowest hazards being at a SBP of 130–139mmHg
[24], which is equivalent to our standard treatment group. In
SPRINT, this U-shaped function was not possible to test due
to the two-group design with widely different BP targets
[25]. Finally, in the latest hypertension guideline of SIGN,
reducing SBP to less than 130mmHg is not recommended
as ‘this brings limited additional benefits and causes signifi-
cant adverse effects’ [7,22]. In the SPRINT cohort, intensive
treatment was associated with a three-fold increase in
chronic kidney disease. In SPRINT, patients were closely
monitored and the adverse effects did not coincide with loss
in follow-up. However, in routine clinical practice, the
adverse effects could lead to discontinuation of the inten-
sive treatment and thereby losing the cardiac benefit it gave
in the first place [25]. The presence of adverse effects could
also lead to polypharmacy and increase in healthcare
utilization with unknown long-term kidney outcomes
[26]. Thus, previous research supports our THIN results
that on average clinical outcomes are not improvedwith the
intensive treatment of SBP compared with the standard
treatment and that the optimal SBP target seems to be less
than 140mmHg in treated hypertensive patients.
Strengths and limitations
The current study had access to SPRINT data [4] and primary
care data that were representative of the United Kingdom
[9,10]. This study selected THIN patients who were similar
to those treated in SPRINT, where one cohort had the exact
same study period and one cohort had an extended study
period. This meant that the short-term and long-term sur-
vival and CKD prospects associated with intensive treat-
ment of SBP could be estimated in patients seen in routine
clinical practice in the United Kingdom and compared with
the original clinical trial.
The main limitation of this study is the difficulty of
directly comparing results of a clinical trial with that of
an observational cohort study based on administrative data
due to the different study designs [8]. With clinical trials,
treatments are randomly assigned, although in SPRINT this
was not blinded for the patients or professionals. In theory,
randomization ensures that all factors affecting the outcome
are evenly balanced across treatment arms, so that the
difference in outcome between the arms is due to the effect
of the treatment. With clinical studies based on administra-
tive data, treatments are not randomly assigned and there
could be selection bias where treatment groups differ in
factors affecting the outcome. In our THIN cohorts, the
main known difference between patients with a SBP
reduced to 140mmHg or less or to 120mmHg or less
was that a higher percentage of the latter group were
treated for CVD, which included antihypertensive treat-
ment. In our study, selection bias was minimized by regres-
sion analyses adjusting for known confounders of the effect
of antihypertensive treatment associated with survival and
CKD prospects, including CVD and related treatments.
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Furthermore, the sensitivity analysis based on the propen-
sity score of receiving intensive treatment suggests that the
results are robust to selection bias. Even though the survival
models performed well, there will be some residual con-
founding. In THIN, prescription changes could signify
sicker patients and lower BP readings could signify unwell
patients. Other differences between the SPRINT and THIN
cohorts were that SPRINT patients had to be at an increased
cardiac risk at baseline; BP was measured differently; and
follow-up BP stayed at target levels in SPRINT but not in
THIN. Finally, the statistical analyses excluded patients with
missing values. The percentage of patients excluded was
limited in SPRINT and would not have altered the results. In
THIN, however, a larger percentage of patients were
excluded due to missing smoking status, which may have
resulted in selecting sicker study population [27].
Recommendations
The study’s findings suggest that in a country where there is
universal access to healthcare, such as the UK National
Health Services, routine patients aged 50–90 years with
hypertension but who are otherwise healthy with respect to
cancer, CKD, dementia, diabetes, heart failure, or stroke, do
not benefit from intensive treatment of SBP. In fact, lower-
ing the SBP too far down, such as less than 120mmHg,
could increase the hazard of CKD and mortality. However,
if patients are closely monitored as with SPRINT, hyperten-
sive patients who are at high cardiac risk might benefit from
intensive antihypertensive treatment.
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